Two antiviral drugs are available in Australia, but one is prescribed more routinely. Here’s what you need to know as we navigate the eighth COVID wave.
Articles on Molnupiravir
Displaying all articles
Analysis of Victoria’s winter COVID wave found Paxlovid and Lagevrio reduced the risk of hospitalisation and death. The results were better for Paxlovid, but not everyone can take it.
We hear a lot about drug-resistant bacteria. The same thing can happen with viruses.
According to a letter from Biden’s doctor, the president has a runny nose, mild fatigue and a slight cough. The letter also noted that Biden began taking an antiviral drug the morning he tested positive.
Just as access to vaccines was vastly more difficult for low-income countries, the same is now true for the virus’ treatments: at potentially great cost to the world.
The drug has been authorised for the use in the UK and elsewhere, but some are calling for further testing.
Both companies say their drugs will work against the Omicron variant, though this is based on preliminary, lab-based research.
Merck and Pfizer both have oral antiviral pills under review by the FDA. Such treatments could help turn the tide of the pandemic.
Merck announced preliminary data suggesting the drug reduced the risk of hospitalisation and death by 50%.
Top contributors
-
Professor of Pharmaceutical Chemistry, Macquarie University
-
Assistant Professor of Infectious Diseases, University of Virginia
-
Professor of Cancer Virology, University of Leeds
-
Associate Professor and Chief Health Officer - COVID and Health Emergencies, Burnet Institute
-
Pharmacist and PhD Candidate, University of Sydney
-
PhD candidate, La Trobe University and Unit Head, Nossal Institute for Global Health, The University of Melbourne
-
Associate Lecturer, Sydney Pharmacy School, University of Sydney
-
Adjunct Clinical Professor, Monash University
-
Director, WHO Collaborating Centre for Viral Hepatitis, The Peter Doherty Institute for Infection and Immunity
-
Associate Professor in Pharmacology, University of Sydney
-
Professor of Public Health, La Trobe University
-
Postdoctoral Research Fellow, RNA Biology and Biochemistry, University of Sussex
-
PhD candidate at The Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne